.svg)
Retatrutide Is NOT Ozempic. Pathologist Explains
A triple board-certified pathologist breaks down the triple-receptor mechanism and liver-fat data — with trial context separated from the hype.
Our Take
What this video covers
- Why retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors, unlike Ozempic (GLP-1 only) or Mounjaro (GLP-1 + GIP).
- The glucagon paradox — why adding a "sugar-raising" hormone drives weight loss through thermogenesis.
- Liver-fat reduction data and what "power-washing the organ" actually refers to mechanistically.
- Side-effect profile — heart-rate changes, GI effects, and an emerging anhedonia signal worth watching.
Where retatrutide actually stands
As of mid-2026, retatrutide remains in Phase 3 trials. Eli Lilly's TRIUMPH-1 readout showed an average 28.3% body-weight reduction over 80 weeks at the top dose, with nearly half of participants losing more than 30% — figures the company compares to bariatric surgery. The drug has not been submitted for FDA approval, and the earliest realistic market availability is 2027.
Anything sold as retatrutide today comes from the grey market, where purity, dosing, and even the identity of the compound are unverified. Poison-control exposures rose sharply through early 2026 as unregulated use spread.
Disclaimer
Retatrutide is an investigational drug. It is not approved by the FDA and is not legally available outside clinical trials. This page is informational and is not medical advice or an offer to sell.
Register your interest in Retatrutide
Retatrutide is currently not available, but once it is approved, you’ll be the first to get notified. Sign up now and stay informed.
Simple one-time sign-up
Early access to availability updates
Exclusive status among the first users
Advantage over non-registered users
Disclaimer: This is not medical advice. Retatrutide is investigational and not FDA-approved. Consult your doctor. Full Medical Disclaimer.